BRPI0717347A2 - Compostos de cb1 - Google Patents
Compostos de cb1Info
- Publication number
- BRPI0717347A2 BRPI0717347A2 BRPI0717347-4A2A BRPI0717347A BRPI0717347A2 BR PI0717347 A2 BRPI0717347 A2 BR PI0717347A2 BR PI0717347 A BRPI0717347 A BR PI0717347A BR PI0717347 A2 BRPI0717347 A2 BR PI0717347A2
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/38—2-Pyrrolones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86254006P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/082042 WO2008070306A2 (en) | 2006-10-23 | 2007-10-22 | 1,5-diphenyl-3-benzylamin0-1,5-dihydr0pyrr0lidin-2-0ne as cb1 receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0717347A2 true BRPI0717347A2 (pt) | 2014-01-14 |
Family
ID=39386481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0717347-4A2A BRPI0717347A2 (pt) | 2006-10-23 | 2007-10-22 | Compostos de cb1 |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8168659B2 (https=) |
| EP (2) | EP2099784B1 (https=) |
| JP (2) | JP5331002B2 (https=) |
| KR (2) | KR101088229B1 (https=) |
| CN (2) | CN101528733B (https=) |
| AR (1) | AR063497A1 (https=) |
| AT (1) | ATE492543T1 (https=) |
| AU (1) | AU2007329808B2 (https=) |
| BR (1) | BRPI0717347A2 (https=) |
| CA (2) | CA2667372C (https=) |
| CL (1) | CL2007003002A1 (https=) |
| CY (1) | CY1111140T1 (https=) |
| DE (1) | DE602007011495D1 (https=) |
| DK (2) | DK2094684T3 (https=) |
| EA (2) | EA015175B1 (https=) |
| ES (2) | ES2356025T3 (https=) |
| MX (2) | MX2009004053A (https=) |
| PE (1) | PE20080926A1 (https=) |
| PL (2) | PL2094684T3 (https=) |
| PT (2) | PT2099784E (https=) |
| SI (2) | SI2094684T1 (https=) |
| TW (1) | TW200825067A (https=) |
| WO (2) | WO2008070305A2 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200825067A (en) * | 2006-10-23 | 2008-06-16 | Lilly Co Eli | CB1 compounds |
| SI2280961T1 (sl) * | 2008-04-22 | 2012-11-30 | Lilly Co Eli | Spojine difenil pirolidin ona kot ligandi cb |
| EA201071222A1 (ru) | 2008-04-22 | 2011-12-30 | Эли Лилли Энд Компани | Соединения 1,5-дифенилпирролидин-2-она в качестве лигандов cb-1 |
| US20110280813A1 (en) * | 2008-11-13 | 2011-11-17 | Alice Prince | Neuraminidase inhibitors and uses thereof |
| EP2593477A2 (en) * | 2010-07-15 | 2013-05-22 | Oleg Iliich Epshtein | Pharmaceutical compositions and methods of treatment |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| US20240158384A1 (en) * | 2020-12-14 | 2024-05-16 | The Board Of Trustees Of The Leland Stanford Junior University | Cb2 receptor agonists |
| WO2023205180A1 (en) | 2022-04-19 | 2023-10-26 | Nurix Therapeutics, Inc. | Biomarkers for cbl, and compositions and methods for their use |
| US20230414598A1 (en) | 2022-06-22 | 2023-12-28 | Nurix Therapeutics, Inc. | Combination therapies with cbl-b inhibitor compounds and antiemetic agents |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200533657A (en) * | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| HRP20080689T3 (hr) * | 2004-02-19 | 2009-05-31 | Solvay Pharmaceuticals B.V. | Imidazolinski derivati sa cb1-antagonističkom aktivnosti |
| US20060035245A1 (en) * | 2004-04-20 | 2006-02-16 | Ason Brandon L | Modulators of enzymatic nucleic acid elements mobilization |
| WO2007020502A2 (en) | 2005-08-16 | 2007-02-22 | Pharmacia & Upjohn Company Llc | Cannabinoid receptor ligands and uses thereof |
| TW200825067A (en) * | 2006-10-23 | 2008-06-16 | Lilly Co Eli | CB1 compounds |
-
2007
- 2007-10-18 TW TW096139051A patent/TW200825067A/zh unknown
- 2007-10-18 CL CL200703002A patent/CL2007003002A1/es unknown
- 2007-10-18 AR ARP070104628A patent/AR063497A1/es unknown
- 2007-10-18 PE PE2007001418A patent/PE20080926A1/es not_active Application Discontinuation
- 2007-10-22 BR BRPI0717347-4A2A patent/BRPI0717347A2/pt not_active IP Right Cessation
- 2007-10-22 DE DE602007011495T patent/DE602007011495D1/de active Active
- 2007-10-22 CA CA2667372A patent/CA2667372C/en not_active Expired - Fee Related
- 2007-10-22 JP JP2009533586A patent/JP5331002B2/ja not_active Expired - Fee Related
- 2007-10-22 CN CN2007800394514A patent/CN101528733B/zh not_active Expired - Fee Related
- 2007-10-22 EA EA200970405A patent/EA015175B1/ru not_active IP Right Cessation
- 2007-10-22 WO PCT/US2007/082041 patent/WO2008070305A2/en not_active Ceased
- 2007-10-22 SI SI200730538T patent/SI2094684T1/sl unknown
- 2007-10-22 AU AU2007329808A patent/AU2007329808B2/en not_active Ceased
- 2007-10-22 PT PT78711967T patent/PT2099784E/pt unknown
- 2007-10-22 DK DK07871197.5T patent/DK2094684T3/da active
- 2007-10-22 DK DK07871196.7T patent/DK2099784T3/da active
- 2007-10-22 CA CA2667210A patent/CA2667210C/en not_active Expired - Fee Related
- 2007-10-22 WO PCT/US2007/082042 patent/WO2008070306A2/en not_active Ceased
- 2007-10-22 US US12/441,570 patent/US8168659B2/en not_active Expired - Fee Related
- 2007-10-22 KR KR1020097008216A patent/KR101088229B1/ko not_active Expired - Fee Related
- 2007-10-22 EA EA200970404A patent/EA015745B1/ru not_active IP Right Cessation
- 2007-10-22 ES ES07871197T patent/ES2356025T3/es active Active
- 2007-10-22 MX MX2009004053A patent/MX2009004053A/es active IP Right Grant
- 2007-10-22 PL PL07871197T patent/PL2094684T3/pl unknown
- 2007-10-22 SI SI200731118T patent/SI2099784T1/sl unknown
- 2007-10-22 CN CN2007800394497A patent/CN101528732B/zh not_active Expired - Fee Related
- 2007-10-22 ES ES07871196T patent/ES2398388T3/es active Active
- 2007-10-22 EP EP07871196A patent/EP2099784B1/en not_active Not-in-force
- 2007-10-22 AT AT07871197T patent/ATE492543T1/de active
- 2007-10-22 PL PL07871196T patent/PL2099784T3/pl unknown
- 2007-10-22 US US12/444,692 patent/US7998985B2/en not_active Expired - Fee Related
- 2007-10-22 EP EP07871197A patent/EP2094684B1/en not_active Not-in-force
- 2007-10-22 KR KR1020097008214A patent/KR101088236B1/ko not_active Expired - Fee Related
- 2007-10-22 PT PT07871197T patent/PT2094684E/pt unknown
- 2007-10-22 MX MX2009004054A patent/MX2009004054A/es active IP Right Grant
- 2007-10-22 JP JP2009533585A patent/JP5331001B2/ja not_active Expired - Fee Related
-
2011
- 2011-01-27 CY CY20111100093T patent/CY1111140T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL301103I1 (nl) | tagraxofusp | |
| LTC2004635I2 (lt) | Pakeistieji enaminokarbonilo junginiai | |
| CR10841A (es) | Imidazotriazinas imidazopirimidinas inhibidores de cinasa | |
| BRPI0815042A2 (pt) | Compostos de pirazol | |
| ATE524477T1 (de) | Aziridinylepothilonverbindungen | |
| DE602006019782D1 (de) | Kapselperforationsmodul | |
| DE602007002544D1 (de) | Nuancierungsmittel | |
| DE602007003893D1 (de) | Kippambossanordnung | |
| DE602007006947D1 (de) | Pyridopyrimidinonderivate | |
| DE602007000258D1 (de) | Kassetteneinspannmechanismus | |
| DE602007001280D1 (de) | Getränkeextraktor | |
| DE502007001629D1 (de) | Rfahren | |
| DE602006020192D1 (de) | Riemenscheibenanorndung | |
| DE502007000218D1 (de) | nsetzungen | |
| DE502007002453D1 (de) | Kunstoffverdichtergehäuse | |
| DE602007000501D1 (de) | Breitbandrichtkoppler | |
| DE602007001098D1 (de) | Spindelmäheinheit | |
| DE602007004080D1 (de) | Tintenstrahlaufnehmer | |
| DE602007007460D1 (de) | Sehkrafttestsystem | |
| DE502007000361D1 (de) | Stanznieteinheit | |
| DE602007000333D1 (de) | Napfbefestigungsvorrichtung | |
| DE602006019150D1 (de) | Riemenscheibenanorndung | |
| BRPI0717347A2 (pt) | Compostos de cb1 | |
| DE112007003147A5 (de) | Rohr-Biegevorrichtung | |
| DE602007005649D1 (de) | Lastansteueranordnung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2329 DE 25-08-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |